202 related articles for article (PubMed ID: 22929054)
41. The perspective of antibiotic therapeutic challenges of brucellosis in the Middle East and North African countries: Current situation and therapeutic management.
Wareth G; Dadar M; Ali H; Hamdy MER; Al-Talhy AM; Elkharsawi AR; Tawab AAAE; Neubauer H
Transbound Emerg Dis; 2022 Sep; 69(5):e1253-e1268. PubMed ID: 35244335
[TBL] [Abstract][Full Text] [Related]
42. [Study on antimicrobial susceptibility of Brucella in a city].
Zuo SW; Ni ZL; Yao YB; Yang RS; Wang SK; Zhou YH
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Dec; 35(12):939-941. PubMed ID: 29495161
[No Abstract] [Full Text] [Related]
43. Molecular characterization and antimicrobial susceptibility of human
Ma HR; Xu HJ; Wang X; Bu ZY; Yao T; Zheng ZR; Sun Y; Ji X; Liu J
Front Microbiol; 2023; 14():1137932. PubMed ID: 37125183
[TBL] [Abstract][Full Text] [Related]
44. In vitro susceptibility of Brucella melitensis to antibiotics.
Rubinstein E; Lang R; Shasha B; Hagar B; Diamanstein L; Joseph G; Anderson M; Harrison K
Antimicrob Agents Chemother; 1991 Sep; 35(9):1925-7. PubMed ID: 1952869
[TBL] [Abstract][Full Text] [Related]
45. Brucella melitensis bacteremia in children: review of 62 cases.
Almuneef M; Memish ZA; Al Shaalan M; Al Banyan E; Al-Alola S; Balkhy HH
J Chemother; 2003 Feb; 15(1):76-80. PubMed ID: 12678419
[TBL] [Abstract][Full Text] [Related]
46. In vitro activities of new macrolides and rifapentine against Brucella spp.
García-Rodríguez JA; Muñoz Bellido JL; Fresnadillo MJ; Trujillano I
Antimicrob Agents Chemother; 1993 Apr; 37(4):911-3. PubMed ID: 8494391
[TBL] [Abstract][Full Text] [Related]
47. Antimicrobial susceptibility of clinical isolates of Brucella.
Mortensen JE; Moore DG; Clarridge JE; Young EJ
Diagn Microbiol Infect Dis; 1986 Jul; 5(2):163-9. PubMed ID: 3720265
[TBL] [Abstract][Full Text] [Related]
48. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.
Shasha B; Lang R; Rubinstein E
Antimicrob Agents Chemother; 1992 May; 36(5):973-6. PubMed ID: 1510422
[TBL] [Abstract][Full Text] [Related]
49. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
Khan MY; Dizon M; Kiel FW
Antimicrob Agents Chemother; 1989 Aug; 33(8):1409-10. PubMed ID: 2802568
[TBL] [Abstract][Full Text] [Related]
50. The expression of type II TA system genes following exposure to the sub-inhibitory concentration of gentamicin and acid stress in Brucella spp.
Amraei F; Narimisa N; Sadeghi Kalani B; Mohammadzadeh R; Lohrasbi V; Masjedian Jazi F
Microb Pathog; 2020 Jul; 144():104194. PubMed ID: 32289464
[TBL] [Abstract][Full Text] [Related]
51. Species-specific PCR for the Diagnosis and Determination of Antibiotic Susceptibilities of
Irajian GR; Masjedian Jazi F; Mirnejad R; Piranfar V; Zahraei Salehi T; Amir Mozafari N; Ghaznavi-Rad E; Khormali M
Iran J Pathol; 2016; 11(3):238-247. PubMed ID: 27799972
[TBL] [Abstract][Full Text] [Related]
52. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
Süzük S; Kaşkatepe B; Avcıküçük H; Aksaray S; Başustaoğlu A
Mikrobiyol Bul; 2015 Oct; 49(4):494-501. PubMed ID: 26649407
[TBL] [Abstract][Full Text] [Related]
53. Modern chemotherapy for brucellosis in humans.
Hall WH
Rev Infect Dis; 1990; 12(6):1060-99. PubMed ID: 2267485
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study.
Erdem H; Ulu-Kilic A; Kilic S; Karahocagil M; Shehata G; Eren-Tulek N; Yetkin F; Celen MK; Ceran N; Gul HC; Mert G; Tekin-Koruk S; Dizbay M; Inal AS; Nayman-Alpat S; Bosilkovski M; Inan D; Saltoglu N; Abdel-Baky L; Adeva-Bartolome MT; Ceylan B; Sacar S; Turhan V; Yilmaz E; Elaldi N; Kocak-Tufan Z; Ugurlu K; Dokuzoguz B; Yilmaz H; Gundes S; Guner R; Ozgunes N; Ulcay A; Unal S; Dayan S; Gorenek L; Karakas A; Tasova Y; Usluer G; Bayindir Y; Kurtaran B; Sipahi OR; Leblebicioglu H
Antimicrob Agents Chemother; 2012 Mar; 56(3):1523-8. PubMed ID: 22155822
[TBL] [Abstract][Full Text] [Related]
55. In vitro efficacy of several antimicrobial combinations against Brucella canis and Brucella melitensis strains isolated from dogs.
Mateu-de-Antonio EM; Martín M
Vet Microbiol; 1995 Jun; 45(1):1-10. PubMed ID: 7653024
[TBL] [Abstract][Full Text] [Related]
56. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
57. In vitro synergistic effects of a short cationic peptide and clinically used antibiotics against drug-resistant isolates of Brucella melitensis.
Mohammadi Azad Z; Moravej H; Fasihi-Ramandi M; Masjedian F; Nazari R; Mirnejad R; Moosazadeh Moghaddam M
J Med Microbiol; 2017 Jul; 66(7):919-926. PubMed ID: 28699872
[TBL] [Abstract][Full Text] [Related]
58. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.
Ariza J; Gudiol F; Pallarés R; Rufí G; Fernández-Viladrich P
Antimicrob Agents Chemother; 1985 Oct; 28(4):548-51. PubMed ID: 4073878
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.
Kilic S; Dizbay M; Cabadak H
J Chemother; 2008 Feb; 20(1):33-7. PubMed ID: 18390405
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
Kassim A; Omuse G; Premji Z; Revathi G
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
